Literature DB >> 25832687

Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: a randomized, phase 2/3 trial in locally advanced nasopharyngeal carcinoma.

Terence Tan1, Wan-Teck Lim2, Kam-Weng Fong3, Shie-Lee Cheah3, Yoke-Lim Soong3, Mei-Kim Ang2, Quan-Sing Ng2, Daniel Tan2, Whee-Sze Ong4, Sze-Huey Tan4, Connie Yip3, Daniel Quah3, Khee-Chee Soo5, Joseph Wee3.   

Abstract

PURPOSE: To compare survival, tumor control, toxicities, and quality of life of patients with locally advanced nasopharyngeal carcinoma (NPC) treated with induction chemotherapy and concurrent chemo-radiation (CCRT), against CCRT alone. PATIENTS AND METHODS: Patients were stratified by N stage and randomized to induction GCP (3 cycles of gemcitabine 1000 mg/m(2), carboplatin area under the concentration-time-curve 2.5, and paclitaxel 70 mg/m(2) given days 1 and 8 every 21 days) followed by CCRT (radiation therapy 69.96 Gy with weekly cisplatin 40 mg/m(2)), or CCRT alone. The accrual of 172 was planned to detect a 15% difference in 5-year overall survival (OS) with a 5% significance level and 80% power.
RESULTS: Between September 2004 and August 2012, 180 patients were accrued, and 172 (GCP 86, control 86) were analyzed by intention to treat. There was no significant difference in OS (3-year OS 94.3% [GCP] vs 92.3% [control]; hazard ratio 1.05; 1-sided P=.494]), disease-free survival (hazard ratio 0.77, 95% confidence interval 0.44-1.35, P=.362), and distant metastases-free survival (hazard ratio 0.80, 95% confidence interval 0.38-1.67, P=.547) between the 2 arms. Treatment compliance in the induction phase was good, but the relative dose intensity for concurrent cisplatin was significantly lower in the GCP arm. Overall, the GCP arm had higher rates of grades 3 and 4 leukopenia (52% vs 37%) and neutropenia (24% vs 12%), but grade 3 and 4 acute radiation toxicities were not statistically different between the 2 arms. The global quality of life scores were comparable in both arms.
CONCLUSION: Induction chemotherapy with GCP before concurrent chemo-irradiation did not improve survival in locally advanced NPC.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25832687     DOI: 10.1016/j.ijrobp.2015.01.002

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  91 in total

1.  Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.

Authors:  Carlos Rodriguez-Galindo; Mark D Krailo; Matthew J Krasin; Li Huang; M Beth McCarville; John Hicks; Farzana Pashankar; Alberto S Pappo
Journal:  J Clin Oncol       Date:  2019-09-25       Impact factor: 44.544

Review 2.  Chemotherapy for Nasopharyngeal Cancer: Neoadjuvant, Concomitant, and/or Adjuvant.

Authors:  Wai Tong Ng; Amy T Y Chang; Sarah W M Lee; Henry C K Sze; Anne W M Lee
Journal:  Curr Treat Options Oncol       Date:  2015-09

Review 3.  The next decade of clinical trials in locoregionally advanced nasopharyngeal carcinoma.

Authors:  Liang Peng; Jin-Qi Liu; Yu-Pei Chen; Jun Ma
Journal:  Br J Radiol       Date:  2019-05-24       Impact factor: 3.039

Review 4.  Which treatment is better than concurrent chemoradiotherapy about survival for stage III or IV locally advanced nasopharyngeal carcinoma? An updated Bayesian network meta-analysis of randomized controlled trials.

Authors:  Lucheng Fang; Licai Shi; Wen Wang; Tingting Hu; Xingwang Rao
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-02-17       Impact factor: 2.503

5.  [The best multimodal treatment for locally advanced nasopharyngeal carcinoma : An update of the MAC-NPC data].

Authors:  Martina Becker-Schiebe; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2017-10       Impact factor: 3.621

6.  A Pairwise Meta-Analysis of Induction Chemotherapy in Nasopharyngeal Carcinoma.

Authors:  Pu-Yun OuYang; Xiao-Min Zhang; Xing-Sheng Qiu; Zhi-Qiao Liu; Lixia Lu; Yuan-Hong Gao; Fang-Yun Xie
Journal:  Oncologist       Date:  2019-02-19

7.  What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis.

Authors:  Laureen Ribassin-Majed; Sophie Marguet; Anne W M Lee; Wai Tong Ng; Jun Ma; Anthony T C Chan; Pei-Yu Huang; Guopei Zhu; Daniel T T Chua; Yong Chen; Hai-Qiang Mai; Dora L W Kwong; Shie-Lee Cheah; James Moon; Yuk Tung; Kwan-Hwa Chi; George Fountzilas; Jean Bourhis; Jean Pierre Pignon; Pierre Blanchard
Journal:  J Clin Oncol       Date:  2016-12-05       Impact factor: 44.544

Review 8.  Nasopharyngeal carcinoma: an evolving paradigm.

Authors:  Kenneth C W Wong; Edwin P Hui; Kwok-Wai Lo; Wai Kei Jacky Lam; David Johnson; Lili Li; Qian Tao; Kwan Chee Allen Chan; Ka-Fai To; Ann D King; Brigette B Y Ma; Anthony T C Chan
Journal:  Nat Rev Clin Oncol       Date:  2021-06-30       Impact factor: 66.675

9.  Accuracy of a Staging System for Prognosis of 5-Year Survival of Patients With Nasopharyngeal Carcinoma Who Underwent Chemoradiotherapy.

Authors:  Chung-I Huang; Li-Fu Chen; Shih-Lun Chang; Hung-Chang Wu; Wei-Chen Ting; Ching-Chieh Yang
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2017-11-01       Impact factor: 6.223

10.  Association of tumor downstaging after neoadjuvant chemotherapy with survival in patients with locally advanced nasopharyngeal carcinoma: a retrospective cohort study.

Authors:  Weifeng Wang; Shaohua Peng; Huanliang Wu; Yunxiu Luo; Feng Yuan; Zhiren Lin; Gang Cheng; Shengmin Chen
Journal:  J Cancer Res Clin Oncol       Date:  2021-06-23       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.